Global Neurological Disorder Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Neurological Disorder Drugs market size was valued at USD 2018.2 million in 2023 and is forecast to a readjusted size of USD 3532.5 million by 2030 with a CAGR of 8.3% during review period.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The Global Info Research report includes an overview of the development of the Neurological Disorder Drugs industry chain, the market status of Hospital (Antipsychotic, Hypnotic & Sedative), Clinic (Antipsychotic, Hypnotic & Sedative), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurological Disorder Drugs.
Regionally, the report analyzes the Neurological Disorder Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurological Disorder Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurological Disorder Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurological Disorder Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antipsychotic, Hypnotic & Sedative).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurological Disorder Drugs market.
Regional Analysis: The report involves examining the Neurological Disorder Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurological Disorder Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurological Disorder Drugs:
Company Analysis: Report covers individual Neurological Disorder Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurological Disorder Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Neurological Disorder Drugs. It assesses the current state, advancements, and potential future developments in Neurological Disorder Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurological Disorder Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Neurological Disorder Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurological Disorder Drugs, with revenue, gross margin and global market share of Neurological Disorder Drugs from 2019 to 2024.
Chapter 3, the Neurological Disorder Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Neurological Disorder Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurological Disorder Drugs.
Chapter 13, to describe Neurological Disorder Drugs research findings and conclusion.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
The Global Info Research report includes an overview of the development of the Neurological Disorder Drugs industry chain, the market status of Hospital (Antipsychotic, Hypnotic & Sedative), Clinic (Antipsychotic, Hypnotic & Sedative), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurological Disorder Drugs.
Regionally, the report analyzes the Neurological Disorder Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurological Disorder Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurological Disorder Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurological Disorder Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Antipsychotic, Hypnotic & Sedative).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurological Disorder Drugs market.
Regional Analysis: The report involves examining the Neurological Disorder Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurological Disorder Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurological Disorder Drugs:
Company Analysis: Report covers individual Neurological Disorder Drugs players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurological Disorder Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Neurological Disorder Drugs. It assesses the current state, advancements, and potential future developments in Neurological Disorder Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurological Disorder Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neurological Disorder Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Antipsychotic
- Hypnotic & Sedative
- Analgesics
- Anticoagulants
- Others
- Hospital
- Clinic
- Novartis
- GlaxoSmithKline
- Merck & Co.
- Bayer
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceutical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Neurological Disorder Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurological Disorder Drugs, with revenue, gross margin and global market share of Neurological Disorder Drugs from 2019 to 2024.
Chapter 3, the Neurological Disorder Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Neurological Disorder Drugs market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurological Disorder Drugs.
Chapter 13, to describe Neurological Disorder Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Neurological Disorder Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neurological Disorder Drugs by Type
1.3.1 Overview: Global Neurological Disorder Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Neurological Disorder Drugs Consumption Value Market Share by Type in 2023
1.3.3 Antipsychotic
1.3.4 Hypnotic & Sedative
1.3.5 Analgesics
1.3.6 Anticoagulants
1.3.7 Others
1.4 Global Neurological Disorder Drugs Market by Application
1.4.1 Overview: Global Neurological Disorder Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Neurological Disorder Drugs Market Size & Forecast
1.6 Global Neurological Disorder Drugs Market Size and Forecast by Region
1.6.1 Global Neurological Disorder Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Neurological Disorder Drugs Market Size by Region, (2019-2030)
1.6.3 North America Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Neurological Disorder Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurological Disorder Drugs Product and Solutions
2.1.4 Novartis Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novartis Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neurological Disorder Drugs Product and Solutions
2.2.4 GlaxoSmithKline Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Merck & Co.
2.3.1 Merck & Co. Details
2.3.2 Merck & Co. Major Business
2.3.3 Merck & Co. Neurological Disorder Drugs Product and Solutions
2.3.4 Merck & Co. Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Merck & Co. Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Neurological Disorder Drugs Product and Solutions
2.4.4 Bayer Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Bayer Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Neurological Disorder Drugs Product and Solutions
2.5.4 AstraZeneca Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Neurological Disorder Drugs Product and Solutions
2.6.4 Boehringer Ingelheim Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Teva Pharmaceutical
2.7.1 Teva Pharmaceutical Details
2.7.2 Teva Pharmaceutical Major Business
2.7.3 Teva Pharmaceutical Neurological Disorder Drugs Product and Solutions
2.7.4 Teva Pharmaceutical Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Teva Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neurological Disorder Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Neurological Disorder Drugs by Company Revenue
3.2.2 Top 3 Neurological Disorder Drugs Players Market Share in 2023
3.2.3 Top 6 Neurological Disorder Drugs Players Market Share in 2023
3.3 Neurological Disorder Drugs Market: Overall Company Footprint Analysis
3.3.1 Neurological Disorder Drugs Market: Region Footprint
3.3.2 Neurological Disorder Drugs Market: Company Product Type Footprint
3.3.3 Neurological Disorder Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neurological Disorder Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Neurological Disorder Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Neurological Disorder Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Neurological Disorder Drugs Consumption Value by Type (2019-2030)
6.2 North America Neurological Disorder Drugs Consumption Value by Application (2019-2030)
6.3 North America Neurological Disorder Drugs Market Size by Country
6.3.1 North America Neurological Disorder Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Neurological Disorder Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Neurological Disorder Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Neurological Disorder Drugs Consumption Value by Type (2019-2030)
7.2 Europe Neurological Disorder Drugs Consumption Value by Application (2019-2030)
7.3 Europe Neurological Disorder Drugs Market Size by Country
7.3.1 Europe Neurological Disorder Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.3 France Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region
8.3.1 Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2019-2030)
8.3.2 China Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.5 India Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Neurological Disorder Drugs Consumption Value by Type (2019-2030)
9.2 South America Neurological Disorder Drugs Consumption Value by Application (2019-2030)
9.3 South America Neurological Disorder Drugs Market Size by Country
9.3.1 South America Neurological Disorder Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Neurological Disorder Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country
10.3.1 Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Neurological Disorder Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Neurological Disorder Drugs Market Drivers
11.2 Neurological Disorder Drugs Market Restraints
11.3 Neurological Disorder Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Neurological Disorder Drugs Industry Chain
12.2 Neurological Disorder Drugs Upstream Analysis
12.3 Neurological Disorder Drugs Midstream Analysis
12.4 Neurological Disorder Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Neurological Disorder Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neurological Disorder Drugs by Type
1.3.1 Overview: Global Neurological Disorder Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Neurological Disorder Drugs Consumption Value Market Share by Type in 2023
1.3.3 Antipsychotic
1.3.4 Hypnotic & Sedative
1.3.5 Analgesics
1.3.6 Anticoagulants
1.3.7 Others
1.4 Global Neurological Disorder Drugs Market by Application
1.4.1 Overview: Global Neurological Disorder Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Neurological Disorder Drugs Market Size & Forecast
1.6 Global Neurological Disorder Drugs Market Size and Forecast by Region
1.6.1 Global Neurological Disorder Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Neurological Disorder Drugs Market Size by Region, (2019-2030)
1.6.3 North America Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Neurological Disorder Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Neurological Disorder Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurological Disorder Drugs Product and Solutions
2.1.4 Novartis Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novartis Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Neurological Disorder Drugs Product and Solutions
2.2.4 GlaxoSmithKline Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Merck & Co.
2.3.1 Merck & Co. Details
2.3.2 Merck & Co. Major Business
2.3.3 Merck & Co. Neurological Disorder Drugs Product and Solutions
2.3.4 Merck & Co. Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Merck & Co. Recent Developments and Future Plans
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer Neurological Disorder Drugs Product and Solutions
2.4.4 Bayer Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Bayer Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Neurological Disorder Drugs Product and Solutions
2.5.4 AstraZeneca Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Neurological Disorder Drugs Product and Solutions
2.6.4 Boehringer Ingelheim Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Teva Pharmaceutical
2.7.1 Teva Pharmaceutical Details
2.7.2 Teva Pharmaceutical Major Business
2.7.3 Teva Pharmaceutical Neurological Disorder Drugs Product and Solutions
2.7.4 Teva Pharmaceutical Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Teva Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neurological Disorder Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Neurological Disorder Drugs by Company Revenue
3.2.2 Top 3 Neurological Disorder Drugs Players Market Share in 2023
3.2.3 Top 6 Neurological Disorder Drugs Players Market Share in 2023
3.3 Neurological Disorder Drugs Market: Overall Company Footprint Analysis
3.3.1 Neurological Disorder Drugs Market: Region Footprint
3.3.2 Neurological Disorder Drugs Market: Company Product Type Footprint
3.3.3 Neurological Disorder Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neurological Disorder Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Neurological Disorder Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Neurological Disorder Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Neurological Disorder Drugs Consumption Value by Type (2019-2030)
6.2 North America Neurological Disorder Drugs Consumption Value by Application (2019-2030)
6.3 North America Neurological Disorder Drugs Market Size by Country
6.3.1 North America Neurological Disorder Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Neurological Disorder Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Neurological Disorder Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Neurological Disorder Drugs Consumption Value by Type (2019-2030)
7.2 Europe Neurological Disorder Drugs Consumption Value by Application (2019-2030)
7.3 Europe Neurological Disorder Drugs Market Size by Country
7.3.1 Europe Neurological Disorder Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.3 France Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Neurological Disorder Drugs Market Size by Region
8.3.1 Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2019-2030)
8.3.2 China Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.5 India Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Neurological Disorder Drugs Consumption Value by Type (2019-2030)
9.2 South America Neurological Disorder Drugs Consumption Value by Application (2019-2030)
9.3 South America Neurological Disorder Drugs Market Size by Country
9.3.1 South America Neurological Disorder Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Neurological Disorder Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Neurological Disorder Drugs Market Size by Country
10.3.1 Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Neurological Disorder Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Neurological Disorder Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Neurological Disorder Drugs Market Drivers
11.2 Neurological Disorder Drugs Market Restraints
11.3 Neurological Disorder Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Neurological Disorder Drugs Industry Chain
12.2 Neurological Disorder Drugs Upstream Analysis
12.3 Neurological Disorder Drugs Midstream Analysis
12.4 Neurological Disorder Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Neurological Disorder Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Neurological Disorder Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Neurological Disorder Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Novartis Company Information, Head Office, and Major Competitors
Table 6. Novartis Major Business
Table 7. Novartis Neurological Disorder Drugs Product and Solutions
Table 8. Novartis Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Novartis Recent Developments and Future Plans
Table 10. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Neurological Disorder Drugs Product and Solutions
Table 13. GlaxoSmithKline Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GlaxoSmithKline Recent Developments and Future Plans
Table 15. Merck & Co. Company Information, Head Office, and Major Competitors
Table 16. Merck & Co. Major Business
Table 17. Merck & Co. Neurological Disorder Drugs Product and Solutions
Table 18. Merck & Co. Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Merck & Co. Recent Developments and Future Plans
Table 20. Bayer Company Information, Head Office, and Major Competitors
Table 21. Bayer Major Business
Table 22. Bayer Neurological Disorder Drugs Product and Solutions
Table 23. Bayer Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Bayer Recent Developments and Future Plans
Table 25. AstraZeneca Company Information, Head Office, and Major Competitors
Table 26. AstraZeneca Major Business
Table 27. AstraZeneca Neurological Disorder Drugs Product and Solutions
Table 28. AstraZeneca Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. AstraZeneca Recent Developments and Future Plans
Table 30. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 31. Boehringer Ingelheim Major Business
Table 32. Boehringer Ingelheim Neurological Disorder Drugs Product and Solutions
Table 33. Boehringer Ingelheim Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Boehringer Ingelheim Recent Developments and Future Plans
Table 35. Teva Pharmaceutical Company Information, Head Office, and Major Competitors
Table 36. Teva Pharmaceutical Major Business
Table 37. Teva Pharmaceutical Neurological Disorder Drugs Product and Solutions
Table 38. Teva Pharmaceutical Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Teva Pharmaceutical Recent Developments and Future Plans
Table 40. Global Neurological Disorder Drugs Revenue (USD Million) by Players (2019-2024)
Table 41. Global Neurological Disorder Drugs Revenue Share by Players (2019-2024)
Table 42. Breakdown of Neurological Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 43. Market Position of Players in Neurological Disorder Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 44. Head Office of Key Neurological Disorder Drugs Players
Table 45. Neurological Disorder Drugs Market: Company Product Type Footprint
Table 46. Neurological Disorder Drugs Market: Company Product Application Footprint
Table 47. Neurological Disorder Drugs New Market Entrants and Barriers to Market Entry
Table 48. Neurological Disorder Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 49. Global Neurological Disorder Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 50. Global Neurological Disorder Drugs Consumption Value Share by Type (2019-2024)
Table 51. Global Neurological Disorder Drugs Consumption Value Forecast by Type (2025-2030)
Table 52. Global Neurological Disorder Drugs Consumption Value by Application (2019-2024)
Table 53. Global Neurological Disorder Drugs Consumption Value Forecast by Application (2025-2030)
Table 54. North America Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 55. North America Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 56. North America Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 57. North America Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 58. North America Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 59. North America Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 60. Europe Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 61. Europe Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 62. Europe Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 63. Europe Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 64. Europe Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 65. Europe Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 66. Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 67. Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 68. Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 69. Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 70. Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 71. Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 72. South America Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 73. South America Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 74. South America Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 75. South America Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 76. South America Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 77. South America Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 79. Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 80. Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 81. Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 82. Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 83. Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 84. Neurological Disorder Drugs Raw Material
Table 85. Key Suppliers of Neurological Disorder Drugs Raw Materials
Table 1. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Neurological Disorder Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Neurological Disorder Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Neurological Disorder Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Novartis Company Information, Head Office, and Major Competitors
Table 6. Novartis Major Business
Table 7. Novartis Neurological Disorder Drugs Product and Solutions
Table 8. Novartis Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Novartis Recent Developments and Future Plans
Table 10. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Neurological Disorder Drugs Product and Solutions
Table 13. GlaxoSmithKline Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GlaxoSmithKline Recent Developments and Future Plans
Table 15. Merck & Co. Company Information, Head Office, and Major Competitors
Table 16. Merck & Co. Major Business
Table 17. Merck & Co. Neurological Disorder Drugs Product and Solutions
Table 18. Merck & Co. Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Merck & Co. Recent Developments and Future Plans
Table 20. Bayer Company Information, Head Office, and Major Competitors
Table 21. Bayer Major Business
Table 22. Bayer Neurological Disorder Drugs Product and Solutions
Table 23. Bayer Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Bayer Recent Developments and Future Plans
Table 25. AstraZeneca Company Information, Head Office, and Major Competitors
Table 26. AstraZeneca Major Business
Table 27. AstraZeneca Neurological Disorder Drugs Product and Solutions
Table 28. AstraZeneca Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. AstraZeneca Recent Developments and Future Plans
Table 30. Boehringer Ingelheim Company Information, Head Office, and Major Competitors
Table 31. Boehringer Ingelheim Major Business
Table 32. Boehringer Ingelheim Neurological Disorder Drugs Product and Solutions
Table 33. Boehringer Ingelheim Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Boehringer Ingelheim Recent Developments and Future Plans
Table 35. Teva Pharmaceutical Company Information, Head Office, and Major Competitors
Table 36. Teva Pharmaceutical Major Business
Table 37. Teva Pharmaceutical Neurological Disorder Drugs Product and Solutions
Table 38. Teva Pharmaceutical Neurological Disorder Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Teva Pharmaceutical Recent Developments and Future Plans
Table 40. Global Neurological Disorder Drugs Revenue (USD Million) by Players (2019-2024)
Table 41. Global Neurological Disorder Drugs Revenue Share by Players (2019-2024)
Table 42. Breakdown of Neurological Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 43. Market Position of Players in Neurological Disorder Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 44. Head Office of Key Neurological Disorder Drugs Players
Table 45. Neurological Disorder Drugs Market: Company Product Type Footprint
Table 46. Neurological Disorder Drugs Market: Company Product Application Footprint
Table 47. Neurological Disorder Drugs New Market Entrants and Barriers to Market Entry
Table 48. Neurological Disorder Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 49. Global Neurological Disorder Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 50. Global Neurological Disorder Drugs Consumption Value Share by Type (2019-2024)
Table 51. Global Neurological Disorder Drugs Consumption Value Forecast by Type (2025-2030)
Table 52. Global Neurological Disorder Drugs Consumption Value by Application (2019-2024)
Table 53. Global Neurological Disorder Drugs Consumption Value Forecast by Application (2025-2030)
Table 54. North America Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 55. North America Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 56. North America Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 57. North America Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 58. North America Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 59. North America Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 60. Europe Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 61. Europe Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 62. Europe Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 63. Europe Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 64. Europe Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 65. Europe Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 66. Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 67. Asia-Pacific Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 68. Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 69. Asia-Pacific Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 70. Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 71. Asia-Pacific Neurological Disorder Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 72. South America Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 73. South America Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 74. South America Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 75. South America Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 76. South America Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 77. South America Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 78. Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 79. Middle East & Africa Neurological Disorder Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 80. Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 81. Middle East & Africa Neurological Disorder Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 82. Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 83. Middle East & Africa Neurological Disorder Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 84. Neurological Disorder Drugs Raw Material
Table 85. Key Suppliers of Neurological Disorder Drugs Raw Materials
LIST OF FIGURES
Figure 1. Neurological Disorder Drugs Picture
Figure 2. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Neurological Disorder Drugs Consumption Value Market Share by Type in 2023
Figure 4. Antipsychotic
Figure 5. Hypnotic & Sedative
Figure 6. Analgesics
Figure 7. Anticoagulants
Figure 8. Others
Figure 9. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Neurological Disorder Drugs Consumption Value Market Share by Application in 2023
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Global Neurological Disorder Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Neurological Disorder Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market Neurological Disorder Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global Neurological Disorder Drugs Consumption Value Market Share by Region (2019-2030)
Figure 17. Global Neurological Disorder Drugs Consumption Value Market Share by Region in 2023
Figure 18. North America Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 21. South America Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Global Neurological Disorder Drugs Revenue Share by Players in 2023
Figure 24. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players Neurological Disorder Drugs Market Share in 2023
Figure 26. Global Top 6 Players Neurological Disorder Drugs Market Share in 2023
Figure 27. Global Neurological Disorder Drugs Consumption Value Share by Type (2019-2024)
Figure 28. Global Neurological Disorder Drugs Market Share Forecast by Type (2025-2030)
Figure 29. Global Neurological Disorder Drugs Consumption Value Share by Application (2019-2024)
Figure 30. Global Neurological Disorder Drugs Market Share Forecast by Application (2025-2030)
Figure 31. North America Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 32. North America Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 33. North America Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 34. United States Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 41. France Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Region (2019-2030)
Figure 48. China Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 51. India Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. South America Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 55. South America Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 56. South America Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 65. Neurological Disorder Drugs Market Drivers
Figure 66. Neurological Disorder Drugs Market Restraints
Figure 67. Neurological Disorder Drugs Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Neurological Disorder Drugs in 2023
Figure 70. Manufacturing Process Analysis of Neurological Disorder Drugs
Figure 71. Neurological Disorder Drugs Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. Neurological Disorder Drugs Picture
Figure 2. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Neurological Disorder Drugs Consumption Value Market Share by Type in 2023
Figure 4. Antipsychotic
Figure 5. Hypnotic & Sedative
Figure 6. Analgesics
Figure 7. Anticoagulants
Figure 8. Others
Figure 9. Global Neurological Disorder Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Neurological Disorder Drugs Consumption Value Market Share by Application in 2023
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Global Neurological Disorder Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Neurological Disorder Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market Neurological Disorder Drugs Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global Neurological Disorder Drugs Consumption Value Market Share by Region (2019-2030)
Figure 17. Global Neurological Disorder Drugs Consumption Value Market Share by Region in 2023
Figure 18. North America Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 21. South America Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Global Neurological Disorder Drugs Revenue Share by Players in 2023
Figure 24. Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players Neurological Disorder Drugs Market Share in 2023
Figure 26. Global Top 6 Players Neurological Disorder Drugs Market Share in 2023
Figure 27. Global Neurological Disorder Drugs Consumption Value Share by Type (2019-2024)
Figure 28. Global Neurological Disorder Drugs Market Share Forecast by Type (2025-2030)
Figure 29. Global Neurological Disorder Drugs Consumption Value Share by Application (2019-2024)
Figure 30. Global Neurological Disorder Drugs Market Share Forecast by Application (2025-2030)
Figure 31. North America Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 32. North America Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 33. North America Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 34. United States Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 41. France Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific Neurological Disorder Drugs Consumption Value Market Share by Region (2019-2030)
Figure 48. China Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 51. India Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. South America Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 55. South America Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 56. South America Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa Neurological Disorder Drugs Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE Neurological Disorder Drugs Consumption Value (2019-2030) & (USD Million)
Figure 65. Neurological Disorder Drugs Market Drivers
Figure 66. Neurological Disorder Drugs Market Restraints
Figure 67. Neurological Disorder Drugs Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of Neurological Disorder Drugs in 2023
Figure 70. Manufacturing Process Analysis of Neurological Disorder Drugs
Figure 71. Neurological Disorder Drugs Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
